leisure time -WSS

leisure time

author：explore 2025-09-30 12:57:17 - browse：4

AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it was spun off from the device maker Abbott Laboratories in 2013, will step down in July. Gonzalez had previously said he would depart when AbbVie had a plan in place to move on from its best-selling drug, Humira, which is now facing competition from cheaper biosimilars.

He will be replaced by Chief Operating Officer Robert Michael, who, like Gonzalez, is a longtime AbbVie executive. Gonzalez, 70, will become executive chairman of the board of directors.

Gonzalez should be a sobering reminder to the drug industry’s critics of how resilient a CEO’s reputation can be. Because while he has been a subject of nearly constant criticism for AbbVie’s handling of Humira and the patents protecting it, investors are likely to remember him fondly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Interest rates are at a 22

WSS

Parkinson’s finding may lead to tests and, someday, treatments

Stoke drug shows lower activity against childhood epilepsy

CDC: Cases of alpha

Dewpoint Therapeutics lays off staff after losing partnerships

Biotech venture capitalists face new demands from investors

eGenesis tests gene

entertainment

leisure time

knowledge

At least 13 dead in Texas as scorching temps continue

Francis Collins on trust in science and how Covid communications failed

Apple is now the first public company to be valued at $3 trillion

EU regulator recommends expanding Mounjaro approval to obesity

The high cost of giving birth even with insurance

Readout Newsletter: Merck, J&J, and long Covid

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Biotech venture capitalists face new demands from investors

At least 13 dead in Texas as scorching temps continue

NIH director takes cautious approach to Biden drug pricing priority

focus

Public health communication lessons from Covid

Readout Newsletter: Merck, J&J, and long Covid

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Timeline: Special counsel's probe into Trump's handling of classified documents

Medicare Advantage today, explained in one chart

Stoke drug shows lower activity against childhood epilepsy

focus

knowledge

hotspot

hotspot